US Immune Checkpoint Inhibitors Market Research Report Information By Type (CTLA-4 Inhibitor, PD-1 Inhibitor, and PD-L1 Inhibitor), By Application (Lung Cancer, Bladder Cancer, Melanoma, Colorectal Cancer, Hodgkin lymphoma, and Others) –Market Forecast Till 2032

US Immune Checkpoint Inhibitors Market Overview

The US immune checkpoint inhibitors market size was valued at USD 12.8 Billion in 2022. The immune checkpoint inhibitors industry is projected to grow from USD 14.9 Billion in 2023 to USD 51.7 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 16.80% during the projected period (2023 - 2032). The rise in the global prevalence of various types of cancers, the increase in the geriatric population around the world, and technological developments in the screening process for cancer are the prominent market drivers anticipated to propel the US immune checkpoint inhibitors market.

Source: MRFR Database, Primary Research, Secondary Research, and Analyst Review

Immune Checkpoint Inhibitors Market Trends

• Expanding product approvals by the regulatory authorities is driving the market growth.

The US immune checkpoint inhibitors market CAGR is expanding due to the increasing product approvals by the regulatory authorities. For instance, in August 2021, the FDA approved the GlaxoSmithKline PD-1 checkpoint inhibitor Jemperli for adults with mismatch repair-deficient recurrent or advanced endometrial cancer. Jemperli is an anti-PD-1 antibody that secures the PD-1 receptor and blocks its relations with the PD-1 ligands PD-L1 and PD-L2. Additionally, the increasing adoption of combinational therapies has driven immune checkpoint inhibitors market revenue. Combinational therapies use multiple treatments, such as chemotherapy and immunotherapy, to target cancer through different mechanisms. This approach aims to enhance treatment efficacy while potentially reducing side effects. The synergistic effects of combining various therapeutic modalities contribute to a better comprehensive and tailored approach to cancer care.

Further, the immune checkpoint inhibitors market growth is experiencing growth owing to the presence of reimbursement policies and heightened awareness leading to increased adoption. Reimbursement policies are crucial in facilitating patient access by alleviating financial burdens. In addition, rising awareness about the efficacy of immune checkpoint inhibitor therapies and their applications in various cancer conditions contributes to greater acceptance among healthcare professionals and patients. This increased awareness and supportive reimbursement frameworks foster a favorable environment for immune checkpoint inhibitor adoption, driving sustained market growth.

Immune Checkpoint Inhibitors Market Segment Insights

Immune Checkpoint Inhibitors Type Insights

The US immune checkpoint inhibitors market segmentation, based on type, includes CTLA-4 inhibitors, PD-1 inhibitors, and PD-L1 inhibitors. The PD-1 inhibitor category held a major market share due to the increasing utilization of PD-1 inhibitors. These inhibitors, such as pembrolizumab and nivolumab, revolutionize cancer treatment by enhancing the body's immune response against tumors. Their efficacy across various cancer types, coupled with ongoing research and clinical trials exploring recent indications, positions PD-1 inhibitors as a pivotal force in shaping the landscape of immune checkpoint inhibitors, driving advancements in cancer immunotherapy in the US.

Figure 1: US Immune Checkpoint Inhibitors Market, by Type, 2022 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Immune Checkpoint Inhibitors Application Insights

The US immune checkpoint Inhibitors market segmentation, based on application, includes lung cancer, bladder cancer, melanoma, colorectal cancer, Hodgkin lymphoma, and others. The lung cancer category held a major market share due to the transformative impact of immunotherapy. These inhibitors, like PD-1 and PD-L1 drugs, show promising efficacy in treating lung cancer by enhancing the body's immune response against cancer cells. The continuous research and development in this field and the FDA approvals for new indications contribute to the market's growth as immunotherapy becomes a pivotal component in the evolving landscape of lung cancer treatment.

Immune Checkpoint Inhibitors Country Insights

The immune checkpoint inhibitors market in the US is propelled by the presence of major key players and huge investment in R&D activities to develop new products with lesser side effects, along with initiatives by the government to encourage innovations to decrease the growing disease burden. This is likely to provide more opportunities for the immune checkpoint inhibitors market growth during the forecast period. Growing approvals for new indications, ongoing clinical research, and the effectiveness of immune checkpoint inhibitors in various cancers fuel market growth. The increased understanding of the immune system's role in cancer defense underlines their significance, positioning them as key participants in the evolving landscape of cancer therapeutics.

Immune Checkpoint Inhibitors Key Market Participants & Competitive Insights

Leading market participants are investing heavily in research and development to enhance their product lines, which will help the immune checkpoint inhibitors market expand even more. Market major participants are also undertaking various strategic activities to improve their footprint, with significant market developments including new product establishment, mergers and acquisitions, contractual agreements, and collaboration with other organizations. The immune checkpoint inhibitors industry must deliver cost-effective items to extend and stay in a more competitive and growing market climate.

Major participants in the immune checkpoint inhibitors market are attempting to extend market demand by investing in research and development operations, including Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Innovent Biologics, Inc., BeiGene, Ltd., Merck KGaA, Regeneron Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Shanghai Junshi Biosciences Co., Ltd., GlaxoSmithKline plc, and AstraZeneca plc.

Key Participants in the Immune Checkpoint Inhibitors market include

• Merck & Co. Inc.


• F. Hoffmann-La Roche Ltd.


• Innovent Biologics Inc.


• BeiGene Ltd.


• Merck KGaA


• Regeneron Pharmaceuticals Inc.


• Bristol-Myers Squibb Company


• Shanghai Junshi Biosciences Co. Ltd.


• GlaxoSmithKline plc


• AstraZeneca plc

Immune Checkpoint Inhibitors Industry Developments

November 2023:Merck & Co., Inc., received US Food and Drug Administration (FDA) approval for KEYTRUDA, anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line antidote of adults with locally cutting-edge unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Immune Checkpoint Inhibitors Market Segmentation

Immune Checkpoint Inhibitors Type Outlook

• 
  

  CTLA-4 Inhibitor

  
  


• 
  

  PD-1 Inhibitor

  
  


• 
  

  PD-L1 Inhibitor

  
  

Immune Checkpoint Inhibitors Application Outlook

• 
  

  Lung Cancer

  
  


• 
  

  Bladder Cancer

  
  


• 
  

  Melanoma

  
  


• 
  

  Colorectal Cancer

  
  


• 
  

  Hodgkin lymphoma

  
  


• 
  

   Others